 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of 
mortality after myocardial infarction?
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT 
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?"
  }
}
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of 
mortality after myocardial infarction?
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?",
    "drug": "phenytoin"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: PHENYTOIN: warnings_and_cautions: 5 WARNINGS AND PRECAUTIONS Withdrawal Precipitated Seizure : May precipitate status epilepticus. Dose reductions or discontinuation should be done gradually.
( 5.2 ) Serious Dermatologic Reactions : Discontinue phenytoin at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should 
not be resumed and alternative therapy should be considered. ( 5.3 ) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan hypersensitivity : If signs or symptoms of 
hypersensitivity are present, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established. ( 5.4 ) Hematopoietic Complications: If occurs, follow-up observation is 
indicated and an alternative antiepileptic treatment should be used. ( 5.7 ) 5. PHENYTOIN: warnings_and_cautions: 1 Cardiovascular Risk Associated with Rapid Infusion Rapid intravenous administration 
of Phenytoin Sodium Injection increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Cardiac arrhythmias have included bradycardia, heart block, 
ventricular tachycardia, and ventricular fibrillation which have resulted in asystole, cardiac arrest, and death. Severe complications are most commonly encountered in critically ill patients, elderly
patients, and patients with hypotension and severe myocardial insufficiency. However, cardiac events have also been reported in adults and children without underlying cardiac disease or comorbidities 
and at recommended doses and infusion rates. Intravenous administration should not exceed 50 mg per minute in adults. In pediatric patients, administer the drug at a rate not exceeding 1 to 3 
mg/kg/min or 50 mg per minute, whichever is slower. PHENYTOIN: warnings_and_cautions: Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, 
these events have also been reported at or below the recommended infusion rate. As non-emergency therapy, Phenytoin Sodium Injection should be administered more slowly as either a loading dose or by 
intermittent infusion. Because of the risks of cardiac and local toxicity associated with intravenous phenytoin, oral phenytoin should be used whenever possible. Because adverse cardiovascular 
reactions have occurred during and after infusions, careful cardiac and respiratory monitoring is needed during and after the administration of intravenous Phenytoin Sodium Injection. Reduction in 
rate of administration or discontinuation of dosing may be needed. 5.2 Withdrawal Precipitated Seizure, Status Epilepticus Antiepileptic drugs should not be abruptly discontinued because of the 
possibility of increased seizure frequency, including status epilepticus. PHENYTOIN: warnings_and_cautions: When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or 
substitution of alternative antiepileptic medication arises, this should be done gradually. However, in the event of an allergic or hypersensitivity reaction, rapid substitution of alternative therapy
may be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class. 5.3 Serious Dermatologic Reactions Serious and sometimes fatal 
dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported with phenytoin treatment. The onset of symptoms is usually within 28 days, but
can occur later. Phenytoin should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed
and alternative therapy should be considered. PHENYTOIN: warnings_and_cautions: If a rash occurs, the patient should be evaluated for signs and symptoms of Drug Reaction with Eosinophilia and Systemic
Symptoms (DRESS)  . Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the 
HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic 
drugs associated with SJS/TEN, including phenytoin.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: adverse_reactions: 6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Cardiovascular Risk Associated with Rapid Infusion  
Withdrawal Precipitated Seizure, Status Epilepticus  Serious Dermatologic Reactions  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity  Hypersensitivity  
Hepatic Injury  Hematopoietic Complications  Local toxicity (Including Purple Glove Syndrome)  Exacerbation of Porphyria  Teratogenicity and Other Harm to the Newborn  Hyperglycemia  The following 
adverse reactions associated with the use of Phenytoin Sodium Injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population
of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most notable signs of toxicity associated with the 
intravenous use of this drug are cardiovascular collapse and/or CNS depression. Hypotension does occur when the drug is administered rapidly by the intravenous route. PHENYTOIN: adverse_reactions: The
rate of administration is very important; it should not exceed 50 mg per minute in adults, and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients  . Body As a Whole: 
Allergic reactions in the form of rash and rarely more serious forms (see Skin and Appendages paragraph below) and DRESS  have been observed. Anaphylaxis has also been reported. There have also been 
reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe cardiovascular events and fatalities have been 
reported with atrial and ventricular conduction depression and ventricular fibrillation. PHENYTOIN: adverse_reactions: Severe complications are most commonly encountered in elderly or critically ill 
patients  . Digestive System: Acute hepatic failure  , toxic hepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. Hematologic and Lymphatic 
System: Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin  . These have included thrombocytopenia, leukopenia, granulocytopenia, 
agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: openfda: spl_id         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: use_in_specific_populations: 8 USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse 
developmental outcomes. ( 5.11 , 8.1 ) Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. ( 8.6 ) 8.1 Pregnancy P regnancy Exposure 
Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as Phenytoin Sodium Injection, during pregnancy. Physicians are 
advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 
1-888-233-2334, and must be done by patients themselves. PHENYTOIN: use_in_specific_populations: Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/ . 
Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal phenytoin exposure is associated with an 
increased incidence of major malformations (including orofacial clefts and cardiac defects). In addition, the fetal hydantoin syndrome a pattern of abnormalities including dysmorphic skull and facial 
features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits has been reported among children born to epileptic women who took phenytoin alone or in 
combination with other antiepileptic drugs during pregnancy  . There have been several reported cases of malignancies, including neuroblastoma, in children whose mothers received phenytoin during 
pregnancy. PHENYTOIN: use_in_specific_populations: Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other manifestations of developmental 
toxicity (including embryofetal death, growth impairment, and behavioral abnormalities) in multiple species at clinically relevant doses . In the U.S. general population, the estimated background risk
of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated 
population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic 
measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage  . However, postpartum restoration of the original 
dosage will probably be indicated. PHENYTOIN: use_in_specific_populations: Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased levels of vitamin 
K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the 
neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately 2.4-fold increased risk for any major malformation in 
children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been reported. The fetal hydantion syndrome is a pattern 
of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental deficiencies. PHENYTOIN: use_in_specific_populations: 
Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth retardation. 
Malformations (including craniofacial, cardiovascular, neural, limb, and digit abnormalities) were observed in rats, rabbits, and mice at doses as low as 100, 75, and 12.5 mg/kg, respectively. 8.2 
Lactation Risk Summary Phenytoin is secreted in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for Phenytoin Sodium 
Injection and any potential adverse effects on the breastfed infant from Phenytoin Sodium Injection or from the underlying maternal condition. 8.         
SOURCE:PHENYTOIN label


CONTENT: PHENYTOIN: pregnancy: 8.1 Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such 
as Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.
This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website 
http://www.aedpregnancyregistry.org/ . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal 
phenytoin exposure is associated with an increased incidence of major malformations (including orofacial clefts and cardiac defects). PHENYTOIN: pregnancy: In addition, the fetal hydantoin syndrome a 
pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits has been reported among 
children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy  . There have been several reported cases of malignancies, including 
neuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other 
manifestations of developmental toxicity (including embryofetal death, growth impairment, and behavioral abnormalities) in multiple species at clinically relevant doses . In the U.S. general 
population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. PHENYTOIN: pregnancy: The background 
risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during 
pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment
of dosage  . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased 
levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before 
delivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately 2. PHENYTOIN: pregnancy: 4-fold 
increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been 
reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental 
deficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth 
retardation. Malformations (including craniofacial, cardiovascular, neural, limb, and digit abnormalities) were observed in rats, rabbits, and mice at doses as low as 100, 75, and 12.5 mg/kg, 
respectively.         
SOURCE:PHENYTOIN label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          )  DO-NOT-KNOW
*(FDAHandler)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?",
    "drug": "phenytoin"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does PHENYTOIN increase or decrease the risk of 
mortality after myocardial infarction?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT 
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) I have sent a query to FDAHandler to obtain 
information on whether PHENYTOIN increases or decreases the risk of mortality after myocardial infarction. However, I have not yet received a response. Without specific data from the FDA label, I 
cannot provide a reliable answer to this question. Therefore, my response at this time is DO-NOT-KNOW. If FDAHandler provides information that can answer the question, I will then be able to give a 
more informed response.
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER 
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(          ) (=>       LLM) (X           )       (          ) 
        Do one of the following:

        1. If you intend to ask a question to FDAAgent:
            Please use the 'add_recipient' tool/function-call
            and specify FDAAgent as your `intended_recipient`.
            DO NOT REPEAT your original message; ONLY specify the 
            `intended_recipient` via this tool/function-call.
        2. If you are ready to have the critic check your answer,
            do so with the `final_answer` tool/function, as I have requested.
        3. If the critic is satisfied and you intend to submit your final answer,
            answer as I have requested, making sure to mark that you are done as usual.

        When you have decided and stated your answer (or lack of one), you must
        ALWAYS specify that you are done using the usual code.

        DO NOT simply acknowldedge these instructions. If you have nothing
        else to say, you MUST EXIT IMMEDIATELY by stating that you are done
        with the usual code (as in #3).
        
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(add_recipient) FUNC: {
  "name": "add_recipient",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler"
  }
}
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) I have sent a query to FDAHandler to obtain 
information on whether PHENYTOIN increases or decreases the risk of mortality after myocardial infarction. However, I have not yet received a response. Without specific data from the FDA label, I 
cannot provide a reliable answer to this question. Therefore, my response at this time is DO-NOT-KNOW. If FDAHandler provides information that can answer the question, I will then be able to give a 
more informed response.
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) I have sent a query to FDAHandler to obtain information on whether PHENYTOIN increases or decreases
the risk of mortality after myocardial infarction. However, I have not yet received a response. Without specific data from the FDA label, I cannot provide a reliable answer to this question. 
Therefore, my response at this time is DO-NOT-KNOW. If FDAHandler provides information that can answer the question, I will then be able to give a more informed response.
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) Your task is to answer questions about various documents.
You will be given various passages from these documents, and asked to answer questions 
about them, or summarize them into coherent answers.
 (FDAHandler)  Entity.USER 
*(FDAHandler)  Entity.AGENT  Entity.AGENT(DocumentHandler) (=>          ) (X           )       (          ) 
                Do one of the following:
                1. Search for relevant text using one of the following tools/functions:
                    `relevant_extracts`, `relevant_search_extracts`, and `drug_category_search`
                2. If you could not find an answer, state that you are done and DO-NOT-KNOW
                    as usual
                3. If you have found an answer, state that you are done and express the answer
                    as usual
                4. If you have no clear remaining question to answer, answer the original
                    question as in #3, and if there was no original question, respond
                    as in #2

                If you have been getting or sending repeated messages, always exit by
                stating that you are done (using the usual code) and say DO-NOT-KNOW.

                DO NOT simply acknowldedge these instructions. If you have nothing
                else to say, you are done and you MUST EXIT IMMEDIATELY by stating that you are done
                with the usual code (you MUST choose #2 or #3, and #4 specifies how to choose).
                THIS IS VERY IMPORTANT. DO THIS IMMEDIATELY BEFORE WAITING FOR ANY FURTHER MESSAGES.
                
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT 
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?",
    "steps": [
      "I sent a query to FDAHandler to obtain information on whether PHENYTOIN increases or decreases the risk of mortality after myocardial infarction.",
      "I have not received a response from FDAHandler, and without specific data from the FDA label, I cannot provide a reliable answer."
    ],
    "answer": "DO-NOT-KNOW"
  }
}
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?",
    "steps": [
      "I sent a query to FDAHandler to obtain information on whether PHENYTOIN increases or decreases the risk of mortality after myocardial infarction.",
      "I have not received a response from FDAHandler, and without specific data from the FDA label, I cannot provide a reliable answer."
    ],
    "answer": "DO-NOT-KNOW",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does PHENYTOIN increase or decrease the risk of mortality after myocardial infarction?
        -----
        Reasoning:
        1. I sent a query to FDAHandler to obtain information on whether PHENYTOIN increases or decreases the risk of mortality after myocardial infarction.
2. I have not received a response from FDAHandler, and without specific data from the FDA label, I cannot provide a reliable answer.
        -----
        Final answer: DO-NOT-KNOW
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": ""
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "",
    "request": "feedback"
  }
}
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) Your reasoning is valid, no feedback was 
provided.
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.USER 
 (orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-PHENYTOIN)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

I requested information from FDAHandler regarding the effect of PHENYTOIN on mortality risk after myocardial infarction but did not receive the necessary data to provide an informed answer. Without 
specific FDA label data, I cannot determine whether PHENYTOIN increases or decreases mortality risk in this context. Therefore, the final answer to the question is DO-NOT-KNOW.
